Department of Internal Medicine, Yale University School of Medicine, 789 Howard Avenue, New Haven, CT 06510, USA.
Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
Clin Chest Med. 2018 Sep;39(3):483-492. doi: 10.1016/j.ccm.2018.04.002.
Venous thromboembolism accounts for significant morbidity and mortality in patients with acute medical illnesses requiring hospital admission. American College of Chest Physicians guidelines recommend prophylaxis with heparins as first line and mechanical methods as second line. The risk of major bleeding with anticoagulants is less than 1% and not significantly different between agents. Although data support the use of all heparins, there is a trend toward superiority of low-molecular-weight heparins (LMWHs). Because acute illness and immobility do not end at hospital discharge, extended-duration therapy with LMWHs and direct oral anticoagulants remains under investigation.
静脉血栓栓塞症在因急性内科疾病需要住院的患者中会导致较高的发病率和死亡率。美国胸科医师学会指南建议使用肝素作为一线预防药物,机械方法作为二线预防药物。抗凝剂治疗的大出血风险小于 1%,且不同药物之间无显著差异。尽管数据支持所有肝素类药物的使用,但低分子肝素(LMWHs)具有优势的趋势。由于急性疾病和活动受限不会在出院时结束,因此 LMWHs 和直接口服抗凝剂的延长治疗时间仍在研究中。